PPT-Cardiovascular risk in NAFLD-

not an equal opportunity implications for womens health Alina M Allen MD Patrick S Kamath MD Joseph J Larson Kymberly D Watt MD Sharonne N Hayes MD Terry M Therneau PhD Mayo Clinic Rochester MN. Gary Michael Idelchik, MD, FACC. April 15, . 2015. Disclosures. I have nothing to disclose.. Outline. What is/are. … . What is Cardiovascular Disease and its manifestations?. What is Coronary Artery Disease (. Christina McConnell, PGY-3. Which of the following is NOT one of the diagnostic criteria for lupus?. Biopsy proven lupus nephritis with a positive ANA. Hemolytic anemia. Psychosis. Single joint swelling. Disease. . s_khalilzadeh. A Novel. Cardiometabolic Risk Factor for Type 2 Diabetes. NAFLD and T2DM. NAFLD is closely associated with features of the metabolic. syndrome and is regarded as the hepatic manifestation. Fatty Liver Disease. Anna Christina Dela Cruz, MD. Division of Digestive Diseases and Nutrition . Conflict of Interest. None. Upon completion of this activity, participants will be able to: . Select appropriate diagnostic testing for the evaluation of gastrointestinal comorbidities in patients with diabetes.. adults. Dr.mousavi. -Abadan-. Khordad. 1397 . DEFINITIONS — Patients with nonalcoholic fatty liver disease (NAFLD) . have hepatic . steatosis. , . with or without . inflammation and fibrosis. . In addition, . New Advances for NAFLD/NASH NAFLD: A Spectrum of Disease Who Is at Risk for NAFLD and NASH? Prevalence of NAFLD in Europe Prevalence of NAFLD and NASH Predicted to Increase in Europe What Is the Burden of NAFLD in Europe? Slide 1: . Target. population/question. 2. 09/01/2018. Patients with inflammatory joint disorders, particularly rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. To update the EULAR 2009 cardiovascular disease (. Moderator. Kris V. Kowdley, MD . Director . Liver Institute Northwest . Clinical Professor. Elson S. Floyd College of Medicine. Washington State University. Seattle, Washington . Overview of Discussion. Hepatologist. East & North Hertfordshire NHS Trust. Royal Free London NHS Foundation Trust. ELF Research Group. University College London. Liver disease. Scale of the problem. Liver disease is the 5. William Alazawi MA(. Cantab. ) PhD MRCP. Senior Lecturer and Consultant in . Hepatology. Queen Mary, University of London. Does Liver Disease Matter?. Mortality in England & Wales. Liver-related mortality in under 65s. Page 1 of 20 UnitedHealthcare Commercial Medical Policy Effective 0 6 / 01 / 2022 Proprietary Information of UnitedHealthcare. Copyright 202 2 United HealthCare Services, Inc. UnitedHealthcareComme Rohit . Pai. MD, FRCPC. Gastroenterology and Hepatology. Island Health and Pacific Digestive Health. Clinical Assistant Professor, UBC. Liver Care Clinic, Royal . Jubillee. Hospital. Disclosures. Research: Intercept. A Scientific Statement From the AHA. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM). A systemic disorder characterized by pathophysiologic interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multi-organ dysfunction and a high rate of adverse cardiovascular outcomes.. Diabetes. Hypertension. HDL < 1 . mmol. /L . Triglycerides > 1.7 . mmol. /L. Suspicion of NAFLD ?. Remember normal LFT’s do not rule out liver disease Exclude significant alcohol misuse (intermediate or high risk group in the alcohol related liver disease pathway) before diagnosing NAFLD via this pathway.